GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (TSE:4568) » Definitions » Book Value per Share

Daiichinkyo Co (TSE:4568) Book Value per Share : 円880.40 (As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Book Value per Share?

Daiichinkyo Co's book value per share for the quarter that ended in Mar. 2024 was 円880.40.

During the past 12 months, Daiichinkyo Co's average Book Value Per Share Growth Rate was 16.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 9.90% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 5.80% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Daiichinkyo Co was 16.80% per year. The lowest was -10.90% per year. And the median was 3.60% per year.

Daiichinkyo Co's current price is 円5010.00. Its book value per share for the quarter that ended in Mar. 2024 was 円880.40. Hence, today's PB Ratio of Daiichinkyo Co is 5.69.

During the past 13 years, the highest P/B Ratio of Daiichinkyo Co was 6.59. The lowest was 1.00. And the median was 2.29.


Daiichinkyo Co Book Value per Share Historical Data

The historical data trend for Daiichinkyo Co's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Book Value per Share Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 671.64 663.85 704.76 754.09 880.40

Daiichinkyo Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 754.09 797.91 831.36 827.36 880.40

Competitive Comparison of Daiichinkyo Co's Book Value per Share

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's PB Ratio distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's PB Ratio falls into.



Daiichinkyo Co Book Value per Share Calculation

Daiichinkyo Co's Book Value Per Share for the fiscal year that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1,688,173-0)/1,918
=880.40

Daiichinkyo Co's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1,688,173-0)/1,918
=880.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Daiichinkyo Co  (TSE:4568) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Daiichinkyo Co Book Value per Share Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co (TSE:4568) Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co (TSE:4568) Headlines

No Headlines